Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
LaunchVerdiva Bio launches as a clinical-stage biopharmaceutical company focused on treating obesity and cardiometabolic disorders with over $410M in Series A financing.
Verdiva Bio has been launched with the aim of developing innovative therapies for obesity and cardiometabolic disorders. The company plans to advance its portfolio of next-generation oral and injectable treatments with significant unmet medical needs, backed by an oversubscribed Series A financing of $411M.
Company Information
Company
Verdiva Bio
Location
London, England, United Kingdom
About
Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options. Verdiva’s most advanced therapy is VRB-101, an oral GLP-1 peptide in clinical development that has demonstrated best-in-class efficacy potential in a phase 1 study in Australia, which also confirmed the viability of once-weekly dosing. The Company is also developing a portfolio of amylin molecules, including oral and subcutaneous agonists, and other undisclosed programs that offer the potential for enhanced efficacy, improved tolerability, and healthier weight loss. The Verdiva team will harness the emerging science in gut-brain biology and leverage their history of successful drug development to advance novel therapeutic options aiming to transform the lives of millions living with obesity worldwide.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Verdiva Bio ships something new, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
LondonBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma